Senseonics Holdings, Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2026-03-31; filed 2026-05-07.
0001104659-26-057233
ITEM 1A. : Risk FactorsCurrent report: 10-Q
Period ended 2026-06-30; filed 2026-08-06.
0001104659-26-092056
ITEM 1A. : Risk FactorsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 9 previous paragraphs and 7 current paragraphs.
7 unchanged; 0 reworded; 0 added; 2 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Removed paragraphs (2)
Previous report
The consummation of the European Asset Purchases is subject to conditions that may not be satisfied, and delays or failures in completing the European Closings could adversely affect our business, financial condition and results of operations.
Previous report
On March 12, 2026, we entered into the Local Purchase Agreements with Ascensia, pursuant to which we agreed to acquire certain commercial assets and assume certain related liabilities in Italy, Germany, Spain and Sweden. The closing of each of the European Asset Purchases is subject to the satisfaction or waiver of customary closing conditions, including the obtaining of certain regulatory clearances, consents or non-objection with respect to the transfer of tender contracts and the completion of certain required labor and employment processes. There can be no assurance that these conditions will be satisfied or waived in a timely manner, or at all. Potential delays in consummating the European Closings could result in increased execution costs, diversion of management attention and resources, and prolonged reliance on Ascensia for transition services under the Transition Services Agreement, which could increase our operating expenses. In addition, the assumption of direct commercial responsibility for Eversense in the European Territories involves significant operational risks, including potential disruptions in relationships with employees, patients, prescribers, distributors or regulatory authorities. We will be required to establish or expand local operations, hire or retain qualified personnel, and comply with local regulatory requirements in each of the European Territories. If we are unable to successfully complete the European Asset Purchases or effectively manage the transition of commercial operations, our ability to generate revenue in the European Territories could be materially adversely affected, and we may incur significant costs that could harm our financial condition and results of operations.